Lilly Gains Approval for Zepbound in Sleep Apnea Care

добавлена новая статья Health

2025-09-07 12:00:15 -

Eli Lilly has achieved a monumental medical advancement through ZEPBOUND (tirzepatide), establishing revolutionary benchmarks within sleep disorder clinical practice. The historic FDA approves ZEPBOUND for obstructive sleep apnea authorization in December 2024 introduces the first pharmaceutical solution specifically developed to address this challenging sleep-related respiratory condition....

0 Комментарии 0 Поделились 1Кб Просмотры 0 предпросмотр